TransMedics Group, Inc.

TransMedics Group, Inc.

TMDX·NASDAQ

$69.69

+3.2%
HealthcareMedical - Devices

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

At a Glance

Live Snapshot
Market Cap$2.41B
EPS5.6000
P/E Ratio12.44
Earnings Date07/29/2026

tmdx

Total Assets

Last Annual Value

1.07B

3-Year CAGR

57%

5-Year CAGR

48%

10-Year CAGR

34%

TransMedics Group, Inc.

TransMedics Group, Inc. Competitors Analysis of Total Assets

TMDX · NASDAQ
CompanyTotal Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
1.07B
14.8%51.3%33.8% 
825.89M
12.5%33.4%N/A
893.49M
-1.7%-4.6%20.9%
6.24B
13.7%11.3%13.2%
744.76M
6.2%N/AN/A
1.74B
44.7%23.5%N/A
1.20B
-12.0%-8.1%-0.0%
769.28M
30.4%62.5%N/A
6.33B
20.7%13.7%N/A
3.46B
1.3%3.4%19.0%
IMVT logo
Immunovant, Inc.
NASDAQ:IMVT
957.01M
33.1%18.3%N/A
TransMedics Group, Inc.

TransMedics Group, Inc. Fair Value Envelope

TMDX · NASDAQ

Our analysis suggests that TMDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $69.69, this represents a potential HIDDEN relative to our calculated worth for TransMedics Group, Inc..

Intrinsic Value
Current Price: $69.69